Dataset Information


Mechanism-based corrector combination restores ?F508-CFTR folding and function.

ABSTRACT: The most common cystic fibrosis mutation, ?F508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of ?F508-CFTR misprocessing, has limited clinical benefit and an incompletely understood mechanism, hampering drug development. Given the effect of second-site suppressor mutations, robust ?F508-CFTR correction most likely requires stabilization of NBD1 energetics and the interface between membrane-spanning domains (MSDs) and NBD1, which are both established primary conformational defects. Here we elucidate the molecular targets of available correctors: class I stabilizes the NBD1-MSD1 and NBD1-MSD2 interfaces, and class II targets NBD2. Only chemical chaperones, surrogates of class III correctors, stabilize human ?F508-NBD1. Although VX-809 can correct missense mutations primarily destabilizing the NBD1-MSD1/2 interface, functional plasma membrane expression of ?F508-CFTR also requires compounds that counteract the NBD1 and NBD2 stability defects in cystic fibrosis bronchial epithelial cells and intestinal organoids. Thus, the combination of structure-guided correctors represents an effective approach for cystic fibrosis therapy.

SUBMITTER: Okiyoneda T 

PROVIDER: S-EPMC3840170 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4054004 | BioStudies
2018-01-01 | S-EPMC6435267 | BioStudies
2020-01-01 | S-EPMC7526550 | BioStudies
1000-01-01 | S-EPMC3784376 | BioStudies
2014-01-01 | S-EPMC4467693 | BioStudies
1000-01-01 | S-EPMC4272825 | BioStudies
1000-01-01 | S-EPMC6065411 | BioStudies
1000-01-01 | S-EPMC2663924 | BioStudies
1000-01-01 | S-EPMC4492728 | BioStudies
1000-01-01 | S-EPMC3799575 | BioStudies